Skip to main content

Advertisement

Table 1 Characterization of all liposomes

From: Preparation and Evaluation of Liposomes Co-Loaded with Doxorubicin, Phospholipase D Inhibitor 5-Fluoro-2-Indolyl Deschlorohalopemide (FIPI) and D-Alpha Tocopheryl Acid Succinate (α-TOS) for Anti-Metastasis

Liposomes Particle size PDI Zeta potential Encapsulation efficiency(%) Drug-loading content (‰)
  (nm)   (mv) DOX FIPI TOS DOX FIPI TOS
Blank-lip 88.58 ± 0.27 0.230 ± 0.004 − 13.80 ± 0.66 -
DOX-lip 84.53 ± 0.45 0.225 ± 0.005 − 27.07 ± 0.38 96.83 ± 1.30 1.33 ± 0.01 -
FIPI-lip 93.58 ± 0.43 0.220 ± 0.017 − 31.63 ± 0.40 96.07 ± 1.85 8.76 ± 0.19 -
TOS-lip 108.60 ± 0.75 0.187 ± 0.007 − 50.33 ± 1.61 94.10 ± 0.03 66.92±0.67
DF-lip 102.73 ± 1.16 0.243 ± 0.009 − 27.97 ± 0.67 96.28 ± 2.50 94.80 ± 1.27 1.32 ± 0.03 8.86 ± 0.06 -
DT-lip 108.40 ± 0.87 0.183 ± 0.016 − 59.40 ± 1.22 94.58 ± 2.87 91.29 ± 2.84 1.19 ± 0.06 65.67±0.59
DFT-lip 119.00 ± 0.80 0.188 ± 0.010 − 58.50 ± 1.04 93.45 ± 3.71 91.46 ± 3.71 91.42 ± 1.94 1.19 ± 0.04 8.69 ± 0.19 65.16±0.18
  1. All data presented here were calculated as the mean ± SD (n = 3) for three different preparations